Pharmaceutical Technology23h
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Pharmaceutical Technology23h
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...
Pharmaceutical Technology15h
Merative MarketScan
The FDA has released final draft recommendations for using real-world data and evidence in drug development.